Select Language:
Weight-loss medications like Ozempic and Wegovy have gained significant popularity in recent years, with many individuals relying on these drugs to manage weight and boost overall health. These drugs are part of a class called GLP-1 receptor agonists, which work by decreasing appetite and supporting weight reduction. However, recent research indicates that how consistently people take these medications might be just as crucial as the medication itself.
A study conducted by researchers at the University of Pennsylvania’s Perelman School of Medicine, published in the Journal of Clinical Investigation Insight, examined the effects of stopping and restarting these medications, a common pattern among users. The study tracked what happens when patients pause their treatment and then resume it.
The use of GLP-1 therapies has surged in the U.S., with about one in eight adults trying them for weight loss. Despite their popularity, many users discontinue treatment after some time. Studies reveal that over half of patients stop taking these drugs within two years, often cycling between discontinuation and recommencement.
To understand the impact of this pattern, the researchers conducted a four-month experiment involving overweight mice, divided into two groups. One group received continuous medication throughout the study, while the other followed a stop-and-start pattern—taking the drug for two weeks, stopping for two weeks, and repeating this cycle several times before switching to continuous use.
Initially, both groups lost similar amounts of weight. However, differences emerged over time. The intermittent group regained weight rapidly during abstinence periods and, notably, showed less weight loss upon resuming therapy. Even after switching to uninterrupted use later, they remained approximately 20% heavier than the group that used the medication consistently. This suggests that repeated stopping and starting may diminish the overall effectiveness of these drugs.
The researchers also examined how body composition changed with treatment. Weight loss from GLP-1 drugs includes both fat and muscle mass—about 60% fat, 40% muscle. When weight is regained after stopping treatment, most of the gained weight comes from fat rather than muscle, leading to a shift in body composition. Over time, the body seems to prioritize preserving muscle, reaching a “muscle floor,” where it resists further weight loss to protect muscle mass.
While these findings come from animal studies and require validation in humans, they raise important questions. The results suggest that sustained, consistent use of GLP-1 medications might be more effective than intermittent therapy. They also highlight the importance of maintaining muscle health through proper nutrition and exercise during treatment.
Overall, the research underscores that consistency is key in optimizing the effectiveness of weight-loss drugs. Stopping and restarting may reduce their benefits, emphasizing the potential need for long-term commitment. Future studies will be necessary to confirm these findings in people and explore ways to preserve muscle mass during weight management.
If you’re interested in weight loss strategies, consider looking into studies about how certain foods—like oranges—and natural compounds—such as berries—may help combat obesity, diabetes, and cancer. Additional research also suggests that ginger and green tea could support weight management efforts.
Source: University of Pennsylvania.
ChatGPT
Perplexity
Gemini AI
Grok AI
